Gambian human African trypanosomiasis in North West Uganda. Are we on course for the 2020 target?
Selby R, Wamboga C, Erphas O, Mugenyi A, Jamonneau V, Waiswa C, Torr SJ, Lehane M.
PLoS Negl Trop Dis. 2019 Aug 14;13(8):e0007550. doi: 10.1371/journal.pntd.0007550. eCollection 2019 Aug.
Laboratory-acquired Gambian trypanosomiasis.
Receveur MC, LeBras M, Vincendeau P.
N Engl J Med. 1993 Jul 15;329(3):209-10. doi: 10.1056/NEJM199307153290317.
Pentamidine: a review.
Sands M, Kron MA, Brown RB.
Rev Infect Dis. 1985 Sep-Oct;7(5):625-34. doi: 10.1093/clinids/7.5.625.
Chronic Gambian trypanosomiasis.
Robinson B, Clark RM, King JF, Hurt B, Mohr JA.
South Med J. 1980 Apr;73(4):516-8. doi: 10.1097/00007611-198004000-00032.
Human African trypanosomiasis: Epidemiology and control.
Fèvre EM, Picozzi K, Jannin J, Welburn SC, Maudlin I.
Adv Parasitol. 2006;61:167-221. doi: 10.1016/S0065-308X(05)61005-6.
The epidemiology and control of human African trypanosomiasis.
Pépin J, Méda HA.
Adv Parasitol. 2001;49:71-132. doi: 10.1016/s0065-308x(01)49038-5.
Recent developments in human African trypanosomiasis.
Welburn SC, Odiit M.
Curr Opin Infect Dis. 2002 Oct;15(5):477-84. doi: 10.1097/00001432-200210000-00004.
Beyond Tsetse--Implications for Research and Control of Human African Trypanosomiasis Epidemics.
Welburn SC, Molyneux DH, Maudlin I.
Trends Parasitol. 2016 Mar;32(3):230-241. doi: 10.1016/j.pt.2015.11.008. Epub 2016 Jan 27.
Enantiospecific antitrypanosomal in vitro activity of eflornithine.
Boberg M, Cal M, Kaiser M, Jansson-Löfmark R, Mäser P, Ashton M.
PLoS Negl Trop Dis. 2021 Jul 12;15(7):e0009583. doi: 10.1371/journal.pntd.0009583. eCollection 2021 Jul.
Scaling up of tsetse control to eliminate Gambian sleeping sickness in northern Uganda.
Hope A, Mugenyi A, Esterhuizen J, Tirados I, Cunningham L, Garrod G, Lehane MJ, Longbottom J, Mangwiro TC, Opiyo M, Stanton M, Torr SJ, Vale GA, Waiswa C, Selby R.
PLoS Negl Trop Dis. 2022 Jun 29;16(6):e0010222. doi: 10.1371/journal.pntd.0010222. eCollection 2022 Jun.
